// App-Quantinova.ai

P278 : Real-world experience with an IL-17A blocker in biologic-naïve and biologic-experienced radiographic and non-radiographic axSpA patients

Researchers

Presenter

  • Nicola Booth

Principal Investigators

  • Julie Hill

  • Soyi Liu Leage

  • Christophe Sapin

  • Elizabeth Holdsworth

  • Silvia Antonelli

Medical Centers

  • Adelphi Real World, Adelphi Real World, Bollington, UNITED KINGDOM

  • Eli Lilly and Company, Eli Lilly and Company, Indianapolis, IN

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

Disease

  • Ankylosing spondylitis

  • Axial spondyloarthritis

Biomarkers

  • Interleukin 17A

Drug/Treatment

  • secukinumab

Outcome

  • N/A

Study Design

  • Cross-Sectional

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • Eli Lilly and Company

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved